Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002
Efficacy of omalizumab in patients with concomitant allergic asthma and atopic dermatitis: a pilot study Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
The effect of smoking on the response to nasal antigen challenge in patients with allergic rhinitis Source: Eur Respir J 2002; 20: Suppl. 38, 217s Year: 2002
Omalizumab in allergic and non-allergic patients: results of FENOMA study Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019
A randomized double-blind study of specific immunotherapy (SIT) in patients with seasonal allergic rhinitis: effects on clinical and inflammatory markers Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001
Effect of humanized monoclonal anti-IgE antibody, omalizumab, on allergen challenge-induced nasal response in subjects with allergic rhinitis and allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
Local cytokine profile specifics among patients with BA phenotype, associated to allergic rhinitis: allergic rhinitis and bronchial asthma. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018
Immunotherapy prevents the development of asthma in subjects with allergic rhinitis Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001
Comparison of late allergic inflammatory responses in asthma and rhinitis after nasal and bronchial allergen challenge Source: Eur Respir J 2001; 18: Suppl. 33, 269s Year: 2001
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009
Impact of subcutaneous allergoid AIT on patients with allergic rhinitis and/or asthma: A retrospective real-life, long-term cohort analysis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
A population-based clinical study of allergic and non-allergic asthma Source: Annual Congress 2008 - Markers and triggers of asthma Year: 2008
Treatment of uncontrolled, severe persistent allergic (IgE-mediated) asthma with omalizumab in a real-life setting in Germany Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
The effect of single dose montelukast and desloratadine, alone and in combination, on the allergen induced late airway response in atopic asthma Source: Annual Congress 2008 - New mechanisms in the pathogenesis of asthma and its response to treatment Year: 2008
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001